三种中度分割方案用于临床局限性前列腺癌高剂量率近距离放疗单药治疗的比较
347例局限性前列腺癌患者分别接受45.5 Gy/7次、49 Gy/7次或54 Gy/9次高剂量率组织间近距离放疗单药治疗。各风险组中三种方案的5年生化失败无生存率无显著差异,但49 Gy组≥2级泌尿生殖毒性(20.5%)高于45.5 Gy组(2.4%)和54 Gy组(10.1%)。作者认为这三种方案均可接受。
要点
- 高危组5年生化失败无生存率分别为86.8%、94.1%、88.5%(p=0.2023)
- 中危组分别为90.4%、100%、97.4%(p=0.0818),低危组45.5 Gy组不可评估
- 49 Gy组≥2级泌尿生殖毒性20.5%,高于45.5 Gy组2.4%和54 Gy组10.1%
核心结论
- 三种方案在各风险组中显示等效的肿瘤学结局,但毒性特征不同,作者认为这些方案是局限性前列腺癌可接受的治疗选择。
研究设计与样本
- 共347例患者接受高剂量率组织间近距离放疗单药治疗:45.5 Gy/7次组86例(中位随访131个月),49 Gy/7次组149例(中位随访75.9个月),54 Gy/9次组112例(中位随访68个月)。
主要发现
- 高危组5年生化失败无生存率:45.5 Gy组86.8%、49 Gy组94.1%、54 Gy组88.5%(p=0.2023)。
- 中危组5年生化失败无生存率:45.5 Gy组90.4%、49 Gy组100%、54 Gy组97.4%(p=0.0818);低危组45.5 Gy组不可评估,49 Gy组和54 Gy组均为100%。
- 5年无远处转移生存率:45.5 Gy组94.4%、49 Gy组98.2%、54 Gy组96.3%(p=0.5454);5年总生存率:45.5 Gy组100%、49 Gy组92.8%、54 Gy组99.1%(p=0.0028)。
- 5年累积≥2级胃肠道毒性发生率:45.5 Gy组1.2%、49 Gy组2.7%、54 Gy组3.4%(p=0.5605)。
- ≥2级泌尿生殖毒性:49 Gy组20.5%,高于45.5 Gy组2.4%和54 Gy组10.1%;未检测到4级或5级毒性。
临床怎么用
- 作者认为高剂量率近距离放疗单药治疗采用这些方案是局限性前列腺癌可接受的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Herein, we report the outcomes of 3 schedules of high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy for localized prostate cancer. PATIENTS AND METHODS: A total of 347 patients were treated with 45.5 Gy/7 fractions (n = 86; 45.5 Gy arm, median follow-up time 131 months), 49 Gy/7 fractions (n = 149; 49 Gy arm, 75.9 months), and 54 Gy/9 fractions (n = 112; 54 Gy arm, 68 months). RESULTS: The actuarial 5-year biochemical failure-free survival rates were 86.8%, 94.1%, and 88.5% (p = 0.2023) for the 45.5 Gy, 49 Gy, and 54 Gy arms in the high-risk group; 90.4%, 100%, and 97.4% (p = 0.0818) in the intermediate-risk group; and not available, 100%, and 100% in the low-risk group, respectively. The 5-year distant metastasis-free (and overall) survival rates were 94.4%, 98.2%, and 96.3% (100%, 92.8%, and 99.1%) for the 45.5 Gy, 49 Gy, and 54 Gy arms (p = 0.5454 and p = 0.0028), respectively. At 5 years, accumulated incidence of grade ≥2 gastrointestinal toxicity was 1.2%, 2.7%, and 3.4% for the 45.5 Gy, 49 Gy, and 54 Gy arms (p = 0.5605), respectively. For genitourinary toxicity, the 49 Gy arm showed a higher grade ≥2 toxicity of 20.5% than those observed in the 45.5 Gy (2.4%) and 54 Gy arms (10.1%). No grade 4 or 5 of either type of toxicity was detected. CONCLUSIONS: The 3 schedules showed equivocal outcomes in each risk group, with different toxicity profiles. HDR-BT monotherapy with these schedules is an acceptable treatment option for localized prostate cancer.
引用
- Yamazaki H, Masui K, Suzuki G, et al. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer. Radiother Oncol. 2018. PMID: 30190166. doi:10.1016/j.radonc.2018.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。